BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 29105989)

  • 1. Patient-reported experience of the impact and burden of neuroendocrine tumors: Oceania patient results from a large global survey.
    Leyden J; Pavlakis N; Chan D; Michael M; Clarke S; Khasraw M; Price T
    Asia Pac J Clin Oncol; 2018 Jun; 14(3):256-263. PubMed ID: 29105989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-Reported Experience of Diagnosis, Management, and Burden of Neuroendocrine Tumors: Results From a Large Patient Survey in the United States.
    Wolin EM; Leyden J; Goldstein G; Kolarova T; Hollander R; Warner RRP
    Pancreas; 2017; 46(5):639-647. PubMed ID: 28328615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs.
    Singh S; Granberg D; Wolin E; Warner R; Sissons M; Kolarova T; Goldstein G; Pavel M; Öberg K; Leyden J
    J Glob Oncol; 2017 Feb; 3(1):43-53. PubMed ID: 28717741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient reported experience of the burden of neuroendocrine tumors and impact of eSHINE Patient Support Program on patient quality of life.
    Wakelin K
    Asia Pac J Clin Oncol; 2020 Nov; 16 Suppl 7():3-8. PubMed ID: 33145888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unmet needs in the international neuroendocrine tumor (NET) community: Assessment of major gaps from the perspective of patients, patient advocates and NET health care professionals.
    Leyden S; Kolarova T; Bouvier C; Caplin M; Conroy S; Davies P; Dureja S; Falconi M; Ferolla P; Fisher G; Goldstein G; Hicks RJ; Lawrence B; Majima Y; Metz DC; O'Toole D; Ruszniewski P; Wiedenmann B; Hollander R;
    Int J Cancer; 2020 Mar; 146(5):1316-1323. PubMed ID: 31509608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of Symptoms Burden in Neuroendocrine Tumors: A Population-Based Analysis of Prospective Patient-Reported Outcomes.
    Hallet J; Davis LE; Mahar AL; Law CHL; Isenberg-Grzeda E; Bubis LD; Singh S; Myrehaug S; Zhao H; Beyfuss K; Moody L; Coburn NG
    Oncologist; 2019 Oct; 24(10):1384-1394. PubMed ID: 31270268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health-related quality of life in patients with neuroendocrine tumors: an investigation of treatment type, disease status, and symptom burden.
    Pearman TP; Beaumont JL; Cella D; Neary MP; Yao J
    Support Care Cancer; 2016 Sep; 24(9):3695-703. PubMed ID: 27029477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perceptions of care and patient-reported outcomes in people living with neuroendocrine tumours.
    Beesley VL; Burge M; Dumbrava M; Callum J; Neale RE; Wyld DK
    Support Care Cancer; 2018 Sep; 26(9):3153-3161. PubMed ID: 29594486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The unmet supportive care needs, quality of life, and care experiences of patients with functioning and non-functioning Neuroendocrine tumours (NETs) at early diagnosis.
    Guccione L; Gough K; Drosdowsky A; Price T; Pavlakis N; Wyld D; Ransom D; Michael M; Schofield P
    Patient Educ Couns; 2022 Jan; 105(1):212-220. PubMed ID: 34030927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Living With Neuroendocrine Tumors: Assessment of Quality of Life Through a Mobile Application.
    Adams JR; Ray D; Willmon R; Pulgar S; Dasari A
    JCO Clin Cancer Inform; 2019 Jul; 3():1-10. PubMed ID: 31283354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient experiences of having a neuroendocrine tumour: a qualitative study.
    Feinberg Y; Law C; Singh S; Wright FC
    Eur J Oncol Nurs; 2013 Oct; 17(5):541-5. PubMed ID: 23522828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported tolerance in treatments approved in neuroendocrine tumors: A national survey from the French Group of Endocrine Tumors.
    Plante A; Baudin E; Do Cao C; Hentic O; Dubreuil O; Terrebonne E; Granger V; Smith D; Lombard-Bohas C; Walter T
    Clin Res Hepatol Gastroenterol; 2018 Apr; 42(2):153-159. PubMed ID: 29158141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elicitation of health state utilities in neuroendocrine tumours.
    Swinburn P; Wang J; Chandiwana D; Mansoor W; Lloyd A
    J Med Econ; 2012; 15(4):681-7. PubMed ID: 22364284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors.
    Jiménez-Fonseca P; Carmona-Bayonas A; Martín-Pérez E; Crespo G; Serrano R; Llanos M; Villabona C; García-Carbonero R; Aller J; Capdevila J; Grande E;
    Cancer Metastasis Rev; 2015 Sep; 34(3):381-400. PubMed ID: 26245646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of the Patient Experience with Treatment and Self-management (PETS): a patient-reported measure of treatment burden.
    Eton DT; Yost KJ; Lai JS; Ridgeway JL; Egginton JS; Rosedahl JK; Linzer M; Boehm DH; Thakur A; Poplau S; Odell L; Montori VM; May CR; Anderson RT
    Qual Life Res; 2017 Feb; 26(2):489-503. PubMed ID: 27566732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility and Satisfaction of Using NET VITALS Self-assessment Tool Among Patients With Neuroendocrine Tumors.
    Li D; Imbesi GJ; Yen L; Kim H; Sun CL; Crook CJ; Ballena R; Zhang YH; Allen R; Sedrak M; Singh G
    Pancreas; 2022 Apr; 51(4):319-324. PubMed ID: 35775639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population.
    Beaumont JL; Cella D; Phan AT; Choi S; Liu Z; Yao JC
    Pancreas; 2012 Apr; 41(3):461-6. PubMed ID: 22422138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The German NET-registry: an audit on the diagnosis and therapy of neuroendocrine tumors.
    Ploeckinger U; Kloeppel G; Wiedenmann B; Lohmann R;
    Neuroendocrinology; 2009; 90(4):349-63. PubMed ID: 19776553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-reported outcome measures of the impact of cancer on patients' everyday lives: a systematic review.
    Catt S; Starkings R; Shilling V; Fallowfield L
    J Cancer Surviv; 2017 Apr; 11(2):211-232. PubMed ID: 27834041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aggressive Surgical Approach to the Management of Neuroendocrine Tumors: A Report of 1,000 Surgical Cytoreductions by a Single Institution.
    Woltering EA; Voros BA; Beyer DT; Wang YZ; Thiagarajan R; Ryan P; Wright A; Ramirez RA; Ricks MJ; Boudreaux JP
    J Am Coll Surg; 2017 Apr; 224(4):434-447. PubMed ID: 28088602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.